Coeptis Therapeutics, Inc., along with its wholly owned subsidiary Coeptis Pharmaceuticals, Inc. (together “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. Coeptis was founded in 2017 and is headquartered in Wexford, Pa.
Company profile
Ticker
COEP
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
VININGS HOLDINGS, INC.
SEC CIK
Corporate docs
IRS number
843998117
COEP stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
14 Dec 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
28 Oct 22
DEFM14A
Proxy related to merger
30 Sep 22
8-K
Regulation FD Disclosure
21 Sep 22
DEFA14A
Additional proxy soliciting materials
21 Sep 22
PREM14A
Preliminary proxy related to merger
16 Sep 22
253G2
Offering circular supplement
7 Sep 22
8-K
Entry into a Material Definitive Agreement
7 Sep 22
DEFA14A
Additional proxy soliciting materials
7 Sep 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.88 mm | 3.13 mm | 344.40 k | 269.78 k |
Cash used (since last report) | n/a | n/a | 45.01 mm | 74.90 mm | 8.23 mm | 6.45 mm |
Cash remaining | n/a | n/a | -37.64 mm | -67.53 mm | -861.34 k | 922.42 k |
Runway (months of cash) | n/a | n/a | -20.0 | -21.6 | -2.5 | 3.4 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 35.36 mm |
Total shares | 8.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lena Pharma | 4.25 mm | $17.68 mm |
Lisa Pharma | 4.25 mm | $17.68 mm |